1,385,990 Shares in Abbott Laboratories $ABT Purchased by Danica Pension Livsforsikringsaktieselskab

Danica Pension Livsforsikringsaktieselskab acquired a new position in shares of Abbott Laboratories (NYSE:ABT) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 1,385,990 shares of the healthcare product maker’s stock, valued at approximately $185,640,000. Abbott Laboratories comprises about 2.9% of Danica Pension Livsforsikringsaktieselskab’s portfolio, making the stock its 9th biggest position. Danica Pension Livsforsikringsaktieselskab owned approximately 0.08% of Abbott Laboratories as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of ABT. Cloud Capital Management LLC bought a new stake in shares of Abbott Laboratories during the third quarter valued at approximately $29,000. Guerra Advisors Inc bought a new position in Abbott Laboratories in the 3rd quarter worth approximately $31,000. Anfield Capital Management LLC lifted its holdings in Abbott Laboratories by 81.3% during the 2nd quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock worth $32,000 after buying an additional 104 shares in the last quarter. Delos Wealth Advisors LLC bought a new position in Abbott Laboratories in the 2nd quarter valued at $32,000. Finally, Bridge Generations Wealth Management LLC acquired a new stake in shares of Abbott Laboratories in the 3rd quarter valued at $33,000. 75.18% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Abbott Laboratories news, VP John A. Jr. Mccoy sold 585 shares of Abbott Laboratories stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $67,614.30. Following the transaction, the vice president directly owned 24,628 shares in the company, valued at approximately $2,846,504.24. The trade was a 2.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Daniel J. Starks bought 10,000 shares of the firm’s stock in a transaction on Wednesday, February 4th. The stock was acquired at an average cost of $108.73 per share, with a total value of $1,087,300.00. Following the completion of the purchase, the director owned 6,738,817 shares of the company’s stock, valued at approximately $732,711,572.41. This trade represents a 0.15% increase in their position. The SEC filing for this purchase provides additional information. Insiders have sold 3,055 shares of company stock worth $353,097 over the last ninety days. Insiders own 0.46% of the company’s stock.

Abbott Laboratories Price Performance

Shares of ABT opened at $110.80 on Wednesday. The stock has a market cap of $192.98 billion, a P/E ratio of 29.79, a price-to-earnings-growth ratio of 1.75 and a beta of 0.74. Abbott Laboratories has a 1 year low of $105.27 and a 1 year high of $139.06. The stock’s 50-day moving average price is $113.91 and its two-hundred day moving average price is $123.50. The company has a current ratio of 1.58, a quick ratio of 1.18 and a debt-to-equity ratio of 0.19.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, meeting analysts’ consensus estimates of $1.50. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The company had revenue of $11.46 billion during the quarter, compared to analysts’ expectations of $11.80 billion. During the same period in the prior year, the business posted $1.34 EPS. Abbott Laboratories’s revenue was up 4.4% on a year-over-year basis. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, equities analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date of this dividend is Wednesday, April 15th. Abbott Laboratories’s dividend payout ratio (DPR) is currently 67.74%.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Raymond James Financial cut their price target on Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating on the stock in a research note on Friday, January 23rd. Piper Sandler dropped their price objective on Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating for the company in a report on Friday, January 23rd. Argus cut their target price on shares of Abbott Laboratories from $150.00 to $140.00 in a research report on Tuesday, January 27th. Barclays lowered their price target on shares of Abbott Laboratories from $169.00 to $142.00 and set an “overweight” rating for the company in a research report on Monday, February 2nd. Finally, Oppenheimer dropped their price target on shares of Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating for the company in a research note on Friday, January 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $136.16.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.